利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.008 秒)

    CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME
    1.
    发明公开
    CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME 有权
    4 - [（2,4-二氯-5-甲氧基苯基）氨基] -6-甲氧基-7- [3-（4-甲基-1-哌嗪基）丙氧基] -3-喹啉羧酸乙酯的结晶形式及制备方法 一样

    公开(公告)号：EP1902029A1

    公开(公告)日：2008-03-26

    申请号：EP06774184.3

    申请日：2006-06-28

    申请人： Wyeth

    发明人： TESCONI, Marc, Sadler ,  FEIGELSON, Gregg ,  STRONG, Henry ,  WEN, Hong

    IPC分类号： C07D215/54 ,  A61K31/4709

    CPC分类号： C07D215/54

    摘要： This invention is directed to a crystalline 4-[(2,4-dichloro-5- methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-l-piperazinyl)propoxy]-3- quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 20 angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109ºC to about 115ºC.

    摘要翻译： 本发明涉及结晶的4 - [（2,4-二氯-5-甲氧基苯基）氨基] -6-甲氧基-7- [3-（4-甲基-1-哌嗪基）丙氧基] -3-喹啉甲腈一水合物， 其中显着峰的20个角度（°）在约9.19,11.48,14.32,19.16,19.45,20.46,21.29,22.33,23.96,24.95,25.29,25.84,26.55,27.61和29.51处的x-射线衍射图， 和约109℃至约115℃的转变温度。

    POLYMORPH FORM II OF TANAPROGET
    2.
    发明公开
    POLYMORPH FORM II OF TANAPROGET 审中-公开
    TANAPROGET的多晶型II

    公开(公告)号：EP1874763A2

    公开(公告)日：2008-01-09

    申请号：EP06751521.3

    申请日：2006-04-26

    申请人： Wyeth

    发明人： TESCONI, Marc, Sadler ,  KU, Mannching, Sherry ,  XU, Yan

    IPC分类号： C07D413/04 ,  A61K31/536 ,  A61P5/24 ,  A61P15/00

    CPC分类号： C07D413/04 ,  C07D265/18 ,  C07B2200/13

    摘要： Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Foπn II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

    摘要翻译： Tanaproget多晶型II，制备tanaproget多晶型II的方法，包括tanaproget多晶型物II的药物组合物，II型微粉化的tanaproget多晶型物，以及将II型转化成tanaproget I型的方法。 还提供了避孕，激素替代疗法，刺激食物摄取和治疗或预防子宫肌瘤，良性前列腺肥大，良性和恶性肿瘤疾病，功能失调性出血，子宫平滑肌瘤，子宫内膜异位症，多囊卵巢综合征或癌和腺癌的方法， 将多晶型II给药至哺乳动物受试者。